# Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/randomized-phase-ii-study-of-dacomitinib-pf-00299804-an-irreversible-pan-human/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Suresh S. Ramalingam,Fiona Blackhall,Maciej Krzakowski,Carlos H. Barrios,Keunchil Park,Isabel Bover,Dae Seog Heo,Rafael Rosell,Denis Talbot,Richard C. Frank,Stephen P. Letrent,Ana Ruiz-Garcı́a,Ian W. Taylor,Jane Liang,Alicyn Campbell,Joseph O’Connell,Michael Boyer |
| Citations | 266 |
| DOI | 10.1200/jco.2011.40.9433 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2011.40.9433?role=tab |
| OpenAlex ID | https://openalex.org/W2102743085 |
| PMID | 22753918 |
| Type | article |
| Year | 2012 |

## Paper authors

- [Dae Seog Heo](https://scholariq.org/researchers/dae-seog-heo/)
- [Keunchil Park](https://scholariq.org/researchers/keunchil-park/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.